Surrey Heartlands

Joint Formulary & PAD

Lithium citrate - Bipolar disorder (adults)

You are here : Home > Formulary Search > Lithium citrate - Bipolar disorder (adults)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Not Specified
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :
Important

To be initiated by a specialist.

This entry has not yet been reviewed for inclusion on the joint formulary. However, this information has been published due to the ongoing requirement for prescribers to access the Blue information sheet and other resources that were in place prior to the launch of the joint formulary.

Please refer to the list of agreed formulations and former traffic light status available on the PAD page (accessed by clicking the drug name).

Documentation

Information
Lithium BLUE information Sheet July 2019.pdf

PAD Profile

ChemicalSubstance :
Lithium citrate
Indication :
Bipolar disorder (adults)
Group Name :
Keywords :
Brand Names Include :
Li-Liquid, Priadel liquid
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Other Indications

Below are listed other indications that Lithium citrate is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Bipolar disorder (adults).

Committee Recommendations (1)

22 Jul 19 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey & North West Sussex Area Prescribing Committee agreed the BLUE information sheet for lithium.